Multiple agent therapy for sexual dysfunction

Details Multiple agent therapy for sexual dysfunction Multiple agent therapy for sexual dysfunction

2007-06-26

2007-06-26

Kam, Chih-Min (Department: 1656)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Melanotropin or eledoisin; related peptides

C530S317000, C530S321000, C530S328000, C530S329000, C530S300000, C514S009100, C514S011400, C514S012200, C514S015800, C514S016700, C514S018700, C424S009100, C436S811000

Reexamination Certificate

active

11139730

ABSTRACT:
Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and/or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.

REFERENCES:
patent: 5576290 (1996-11-01), Hadley
patent: 5674839 (1997-10-01), Hruby et al.
patent: 5714576 (1998-02-01), Hruby et al.
patent: 6051555 (2000-04-01), Hadley
patent: 6350430 (2002-02-01), Dooley et al.
patent: 6376509 (2002-04-01), Bakshi et al.
patent: 6579968 (2003-06-01), Blood et al.
patent: 6608082 (2003-08-01), Basu et al.
patent: 6613874 (2003-09-01), Mazur et al.
patent: 6794489 (2004-09-01), Blood et al.
patent: 2003/0069169 (2003-04-01), Macor et al.
patent: 2004/0138136 (2004-07-01), Sharma et al.
patent: 2004/0192676 (2004-09-01), Chen et al.
patent: 2004/0208829 (2004-10-01), Rubsamen et al.
patent: 2004/0266821 (2004-12-01), Ujjainwalla et al.
patent: 2005/0075344 (2005-04-01), Backer et al.
patent: A-0463756 (1995-04-01), None
patent: A-0526004 (1997-10-01), None
patent: A-0995750 (2000-04-01), None
patent: A-0995751 (2005-06-01), None
patent: WO 93/06104 (1993-04-01), None
patent: WO 93/07124 (1993-04-01), None
patent: WO 93/07149 (1993-04-01), None
patent: WO 93/12095 (1993-06-01), None
patent: WO 94/05661 (1994-01-01), None
patent: WO 95/19978 (1995-07-01), None
patent: WO 96/26940 (1996-09-01), None
patent: WO 99/24433 (1999-05-01), None
patent: WO 99/54333 (1999-10-01), None
patent: WO 00/24745 (2000-05-01), None
patent: WO 00/53148 (2000-09-01), None
patent: WO 01/00224 (2001-01-01), None
patent: WO 01/13112 (2001-02-01), None
patent: WO 01/27112 (2001-04-01), None
patent: WO 01/27113 (2001-04-01), None
patent: WO 02/064091 (2002-08-01), None
patent: WO 02/069905 (2002-09-01), None
patent: WO 03/006620 (2003-01-01), None
patent: WO 2004/005324 (2004-01-01), None
patent: WO 2005/079574 (2005-09-01), None
M. E. Hadley et al., Discovery and development of the novel melanogenic drugs, inIntegration of Pharmaceutical Discovery and Development: Case Studies, edited by Borchardt et al., Plenum Press, New York (1998).
R. T. Dorr et al., Evaluation of Melanotan-II, A Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study.Life Sci. 58:1777-1784 (1996).
L. H. T. Van der Ploeg etr al., A Role for the Melanocortin 4 Receptor in Sexual Function.P.N.A.S., 99:11381-11386 (2002).
H. Wessells et al.,J. Urology160:389-393 (1998).
H. Wessells et al.,Urology56:641-646 (2000).
H. Wessells et al.,Intl. J. Impotence Res. 12:S74-S79 (2000).
R. Vernulapalli et al., Activation of Central Melanocortin Receptors by MT-11 Increases Cavernosal Pressure in Rabbits by the Neuronal Release of NO.British Journal of Pharmacology, 134:1705-1710 (2001).
A. Nehra et al., Rationale for Combination Therapy of Intraurethral Prostaglandin E1and Sildenafil in the Salvage of Erectile Dysfunction Patients Desiring Noninvasive Therapy.Int'l Journal of Impotence Research, 14(S1):S38-S42 (2002).
F. Sommer and U. Engelmann, Future Options for Combination Therapy in the Management of Erectile Dysfunction in Older Men.Drugs and Aging, 9:555-564 (2004).
U. Gresser and C.H. Gleiter, Erectile Dysfunction: Comparison of Efficacy and Side Effects of the PDE-5 Inhibitors SIldenafil, Vardenafil and Tadalafil, Review of the Literature.European J. of Med. Res., 7:435-446 (2002).
P.C. Souverein et al., Incidence and Determinants of Sildenafil (dis)continuation: the Dutch Cohort of Sildenafil Users.Int. J. Impot. Res. 14:259-265 (2002).
L.E. Diamond et al., Double-blind, Placebo-Controlled Evaluation of the Safety, Pharmacokinetic Properties and Pharmacodynamic effects of Intranasal PT-141, a Melanocortin Receptor Agonist, in Healthy Males and Patients with Mild-to-Moderate Erectile Dysfunction.Int. J. Impot. Res. 16:51-59 (2004).
Synthetic Peptides: A User's Guide, G. A. Grant, editor, W.H. Freeman & Co., New York, 1992, the teachings of which are incorporated herein by reference, including the text and table set forth at pp. 11 through 24.
V. J. Hruby, F. Al-Obeidi and W. Kazmierski:Biochem. J. 268:249-262, 1990.
C. Toniolo:Int. J. Peptide Protein Res. 35:287-300, 1990.
W. L. Furlow, Prevalence of Impotence in the United States.Med. Aspects Hum. Sex. 19:13-16 (1985.
F. E. Kaiser, Erectile Dysfunction in the Aging Man.Med. Clin. N. Amer. 83:1267-78 (1999).
Rotella D P,J. Med Chem. 43:1257 (2000).
M. E. Hadley et al., Discovery and development of the novel melanogenic drugs, inIntegration of Pharmaceutical Discovery and Development: Case Studies, edited by Borchardt et al., Plenum Press, New York (1998), p. 575-595.
Rotella D P,J. Med Chem. 43:1257-1263 (2000).

Affiliated with

Also associated with

Rating

Multiple agent therapy for sexual dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multiple agent therapy for sexual dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple agent therapy for sexual dysfunction will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3881809